Ballard_2013_Neurology_81_1730

Dementia with Lewy bodies (DLB) accounts for 10% to 15%(1) of the 35 million people worldwide with dementia. Making an accurate diagnosis is clinically important as these individuals have the challenging combination of highly frequent and disruptive psychotic symptoms together with a high risk of severe sensitivity reactions, leading to accelerated decline and often death following antipsychotic exposure. There is some evidence to support a preferential response, particularly of neuropsychiatric symptoms, to cholinesterase inhibitors. Further, the increased frequency of fluctuating confusion and of falls, and postural hypotension, may have important implications for clinical management.(2.)